Types and importance of human papilloma virus vaccine and methods in promoting it for cervical cancer prevention
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20223232Keywords:
Cervical, Cancer, Prevention, HPV, VaccinationAbstract
Cervical cancer continues to be a significant global challenge as it is the fourth major cause of mortality among women. Cervical cancer is primarily caused by repeated human papilloma virus (HPV) infections. Although the incidence and death of cervical cancer have declined in high-income nations, the disease still places a heavy burden on low- and middle-income countries. HPV-16
Cervical cancer continues to be a significant global challenge as it is the fourth major cause of mortality among women. Cervical cancer is primarily caused by repeated human papilloma virus (HPV) infections. Although the incidence and death of cervical cancer have declined in high-income nations, the disease still places a heavy burden on low- and middle-income countries. HPV-16 is responsible for 50% while HPV-18 is responsible for 10% of cervical cancer cases. The introduction of HPV vaccines is limited in developing areas with greater need, despite the fact that they offer a potential alternative for disease control. The purpose of this research is to review the available information about types and importance of HPV vaccine and methods in promoting it for cervical cancer prevention. Three HPV vaccines for prevention of cervical cancer are available including a quadrivalent vaccine that protects against 4 HPV types, and the second is a bivalent vaccine that protects against 2 high-risk oncogenic HPV types and third is a 9-valent vaccine. All three vaccines provide comparable coverage. Preventative vaccinations against the virus, given to women before HPV infection, have proven to be efficient and have the potential to reduce the incidence of cervical cancer. Thus, it is advised to immunize girls aged 9-14 years. The development of the HPV vaccine has made primary cervical cancer prevention possible. Health promotion and education can potentially contribute to increasing the awareness of community regarding cervical cancer prevention and can lead to better utilization of HPV vaccine.
is responsible for 50% while HPV-18 is responsible for 10% of cervical cancer cases. The introduction of HPV vaccines is limited in developing areas with greater need, despite the fact that they offer a potential alternative for disease control. The purpose of this research is to review the available information about types and importance of HPV vaccine and methods in promoting it for cervical cancer prevention. Three HPV vaccines for prevention of cervical cancer are available including a quadrivalent vaccine that protects against 4 HPV types, and the second is a bivalent vaccine that protects against 2 high-risk oncogenic HPV types and third is a 9-valent vaccine. All three vaccines provide comparable coverage. Preventative vaccinations against the virus, given to women before HPV infection, have proven to be efficient and have the potential to reduce the incidence of cervical cancer. Thus, it is advised to immunize girls aged 9-14 years. The development of the HPV vaccine has made primary cervical cancer prevention possible. Health promotion and education can potentially contribute to increasing the awareness of community regarding cervical cancer prevention and can lead to better utilization of HPV vaccine.
References
Zhang H, Jiang T, Gao R. Risk factors of infectious complications after retrograde intrarenal surgery: a retrospective clinical analysis. J Int Med Res. 2020;48(9):300060520956833.
Brisson M, Kim JJ, Canfell K. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):575-90.
Brianti P, De Flammineis E, Mercuri SR. Review of HPV-related diseases and cancers. New Microbiol. 2017;40(2):80-5.
Wipperman J, Neil T, Williams T. Cervical Cancer: Evaluation and Management. Am Fam Pys. 2018;97(7):449-54.
Arbyn M, Weiderpass E, Bruni L. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Heal. 2020;8(2):e191-203.
Andrae B, Andersson TM, Lambert PC. Screening and cervical cancer cure: population based cohort study. BMJ (Clinical research ed). 2012;344:e900.
Johnson CA, James D, Marzan A, Armaos M. Cervical Cancer: An Overview of Pathophysiology and Management. Seminars Oncol Nursing. 2019;35(2):166-74.
Karcheva M, Yordanov A, Kostadinov S. An overview of cervical cancer epidemiology and prevention in Bulgaria. Germs. 2020;10(4):322-7.
Harper DM. Currently approved prophylactic HPV vaccines. Expert review of vaccines. 2009;8(12):1663-79.
Chen J NG, Liu XS. Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: Immunological problems and future directions. Cell Immunol. 2011(269):5-9.
Luxembourg A, Moeller E. 9-Valent human papillomavirus vaccine: a review of the clinical development program. Expert Rev Vaccines. 2017;16(11):1119-39.
Macartney KK, Chiu C, Georgousakis M, Brotherton JM. Safety of human papillomavirus vaccines: a review. Drug Safety. 2013;36(6):393-412.
Bogani G, Leone Roberti Maggiore U, Signorelli M. The role of human papillomavirus vaccines in cervical cancer: Prevention and treatment. Crit Rev Oncol/Hematol. 2018;122:92-7.
Masika MM, Ogembo JG, Chabeda SV, Wamai RG, Mugo N. Knowledge on HPV Vaccine and Cervical Cancer Facilitates Vaccine Acceptability among School Teachers in Kitui County, Kenya. PloS One. 2015;10(8):e0135563.
Kjaer SK, Dehlendorff C, Belmonte F, Baandrup L. Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer. J National Can Institute. 2021;113(10):1329-35.
Acuti Martellucci C, Nomura S, Yoneoka D. Human papillomavirus vaccine effectiveness within a cervical cancer screening programme: cohort study. BJOG. 2021;128(3):532-9.
Murillo R, Ordóñez-Reyes C. Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs. Int J Gynecolog Can. 2019;29(8):1317-26.
Shiko Y, Konno R, Konishi H, Sauvaget C, Ohashi Y, Kakizoe T. Effectiveness of HPV vaccination against the development of high-grade cervical lesions in young Japanese women. BMC Infect Dis. 2020;20(1):808.
Lei J, Ploner A, Elfström KM. HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med. 2020;383(14):1340-8.
Black E, Richmond R. Prevention of Cervical Cancer in Sub-Saharan Africa: The Advantages and Challenges of HPV Vaccination. Vaccines. 2018;6(3).
Kovar CL, Pestaner M, Webb Corbett R, Rose CL. HPV vaccine promotion: Snapshot of two health departments during the COVID-19 pandemic. Pub Heal Nursing (Boston, Mass). 2021;38(5):715-9.
Chen L, Yang X, Huang X. Promoting HPV vaccination on social media: interactive effects of threat, efficacy and social cues. Human Vaccines Immunotherap. 2021;17(11):4442-56.
Tiro JA, Sanders JM, Pruitt SL. Promoting HPV Vaccination in Safety-Net Clinics: A Randomized Trial. Pediatrics. 2015;136(5):850-9.
Kashani BM, Tibbits M, Potter RC, Gofin R, Westman L, Watanabe-Galloway S. Human Papillomavirus Vaccination Trends, Barriers, and Promotion Methods Among American Indian/Alaska Native and Non-Hispanic White Adolescents in Michigan 2006-2015. J Community Heal. 2019;44(3):436-43.
Xu Y, Bi W, Liu T, Jiang Y, Wang Q, Fan R. Factors associated with intention of human papillomavirus vaccination among Chinese college students: implications for health promotion. Human Vaccines Immunotherap. 2021;17(12):5426-32.
McLean HQ, VanWormer JJ, Chow BDW. Improving Human Papillomavirus Vaccine Use in an Integrated Health System: Impact of a Provider and Staff Intervention. J Adolescent Heal. 2017;61(2):252-8.
